LY-364947

Grouped product items
Size Price Qty
5mg
$85.00
10mg
$160.00
Catalog Number : 3965362

description

LY-364947 is a selective inhibitor of transforming growth factor beta pathway and suppresses TGF-Beta dependent growth in the relevant cell lines. It is also reported to inhibit MDA-MB-231 breast cancer cells in a matrigel invasion assay and block chondrogenesis in human stem cells.

Additional Information

Applications:
FA
Synonyms:
TbetaR-I Inhibitor, LY364947, LY 364947, Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor
Formulation:
Crystalline solid
Chemical Name:
4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline
Molecular Formula:

C17H12N4

Molecular Weight:
272.3
CAS Number
396129-53-6
Purity:
≥98%
Storage Conditions:
Product should be kept at -20°C.
References:

S Bansal, S., Celia, C., Ferrati, S., Zabre, E., Ferrari, M., Palapattu, G., & Grattoni, A. (2013). Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations. Current drug targets,14(9), 1061-1069.

Nassar, K., Tura, A., Lueke, J., Lueke, M., & Grisanti, S. (2012). The novel use of LY364947 (LY), a TGF-ß Type I receptor inhibitor, in prevention of proliferative vitreoretinopathy (PVR). Investigative Ophthalmology & Visual Science53(14), 893-893.

Oka, M., Iwata, C., Suzuki, H. I., Kiyono, K., Morishita, Y., Watabe, T., ... & Miyazono, K. (2008). Inhibition of endogenous TGF-β signaling enhances lymphangiogenesis. Blood111(9), 4571-4579.

© BioGems International, Inc. All rights reserved.